New Zealand markets close in 4 hours 19 minutes

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.60+1.53 (+9.52%)
At close: 04:00PM EDT
17.13 -0.47 (-2.67%)
After hours: 07:32PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close16.07
Bid17.13 x 3100
Ask17.90 x 1200
Day's range16.34 - 18.19
52-week range10.81 - 20.50
Avg. volume809,087
Market cap524.445M
Beta (5Y monthly)1.24
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

    Worldwide Ocaliva® non-GAAP adjusted net sales in PBC of $100.4 million; U.S. net sales of $71.8 million representing 5% growth over the prior year quarter Company reissues 2022 financial guidance to reflect impact of sale of international business: Ocaliva non-GAAP adjusted net sales guidance of $325 million to $345 million and non-GAAP adjusted operating expense guidance of $335 million to $365 million Intercept completed the sale of its international business for $405 million in upfront consi

  • GlobeNewswire

    Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022

    MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2022 financial results prior to market open on Wednesday, August 3, 2022. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results. Par

  • GlobeNewswire

    Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

    OCA 25 mg met the agreed primary endpoint of improvement in liver fibrosis without worsening of NASH at 18 months (p<0.0001), consistent with the original REGENERATE analysis OCA 25 mg demonstrated double the response rate in reduction of liver fibrosis without worsening of NASH vs. placebo Includes larger and more robust safety database of 2,477 patients with nearly 1,000 on study drug for 4 years Intercept to resubmit new drug application (NDA) in liver fibrosis due to NASH; pre-submission mee